IGC Pharma, Inc. (IGC)
| Market Cap | 28.26M +15.3% |
| Revenue (ttm) | 1.11M -6.5% |
| Net Income | -6.45M |
| EPS | -0.08 |
| Shares Out | 98.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 644,618 |
| Open | 0.2880 |
| Previous Close | 0.2860 |
| Day's Range | 0.2803 - 0.2919 |
| 52-Week Range | 0.2420 - 0.4985 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 4.13 (+1,344.06%) |
| Earnings Date | May 15, 2026 |
About IGC
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer’s disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare provi... [Read more]
Financial Performance
In fiscal year 2025, IGC Pharma's revenue was $1.27 million, a decrease of -5.50% compared to the previous year's $1.35 million. Losses were -$7.12 million, -45.22% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for IGC stock is "Strong Buy." The 12-month stock price target is $4.13, which is an increase of 1,344.06% from the latest price.
News
IGC Pharma to present new Tau-PET biomarker research at Global Tau conference
IGC Pharma (IGC) announced that it will present new Tau-PET biomarker research at the 2026 Global Tau Conference, taking place May 14-15, 2026, at the Grand Hyatt Washington in Washington,…
IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference
Research highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development. POTOMAC, MD / ACCESS Newswire / May 15, 2026...
IGC Pharma Quarterly report: Q1 2026
IGC Pharma has published its Q1 2026 quarterly earnings report on May 15, 2026.
IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase
Outreach initiative supports awareness of agitation and patient engagement as enrollment approaches completion POTOMAC, MD / ACCESS Newswire / April 28, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("I...
IGC adds Kerwin Medical Center as clinical site for Phase 2 CALMA trial
IGC Pharma (IGC) announced the addition of Kerwin Medical Center in Dallas, Texas as a clinical site in the Company’s Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer’s…
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study POTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc. (NYSE Ame...
IGC Pharma secures Colombian authorization for psilocybin research
IGC Pharma (IGC) announced that on April 9, it received authorization in Colombia to synthesize, formulate, and conduct development activities involving psilocybin at its research and development faci...
IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia
Authorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completion POTOMAC, MD / ACCESS Newswire / April 20, 2026 / IGC Pharma...
IGC Pharma reaches 80% enrollment in Phase 2 CALMA trial
IGC Pharma (IGC) announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer’s disease. This milestone rep...
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
POTOMAC, MD / ACCESS Newswire / April 14, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA cli...
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
POTOMAC, MD / ACCESS Newswire / April 8, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA...
IGC announces activation of new clinical trial sate for Phase 2 CALMA trial
IGC Pharma (IGC) announced the activation of a new clinical trial site at Tandem Clinical Research A Prolerity Network Site in Metairie, Louisiana, for the Company’s ongoing Phase 2 CALMA…
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease
POTOMAC, MD / ACCESS Newswire / April 7, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing innovative treatments for Alzheimer's d...
IGC Pharma enters national media partnership with New to The Street
IGC Pharma (IGC) announced a strategic 12-part national media partnership with New to The Street. The collaboration is designed to enhance IGC Pharma’s visibility across both institutional and retail ...
IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
POTOMAC, MD / ACCESS Newswire / March 30, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, ...
IGC Pharma, New to The Street launch 12-part national media partnership
New to The Street announced a strategic 12-part media partnership with IGC Pharma (IGC). The multi-faceted campaign is designed to elevate IGC Pharma’s visibility across institutional and retail inves...
IGC Pharma reports 9-month revenue $969K
Reports 9-month net loss ($4.1M) vs. ($5.9M) a year ago. “We have surpassed 70% enrollment in the Phase 2 CALMA clinical trial, marking a significant acceleration as the program advances…
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
- Strategic Pivot to Pure-Play Biotech - POTOMAC, MD / ACCESS Newswire / March 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developi...
IGC Pharma to showcase AI platform with ADDI at ADPD 2026
IGC Pharma (IGC) will demonstrate its Agentic Harmonization Assistant, an artificial intelligence platform designed to automate the integration and analysis of complex biomedical datasets, at the Alzh...
IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026
POTOMAC, MD / ACCESS Newswire / March 18, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, ...
IGC Pharma files utility patent applications covering AHA framework
IGC Pharma (IGC) announced the filing of utility patent applications covering the architectural framework of its Agentic Harmonization Assistant, an internally developed AI-based data harmonization sy...
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research
POTOMAC, MD / ACCESS Newswire / February 26, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's diseas...
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets
POTOMAC, MARYLAND / ACCESS Newswire / February 24, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that Ascendiant Capital Markets has issued an updated equity re...
IGC Pharma expands Phase 2 CALMA trial with new clinical site
IGC Pharma (IGC) announced the addition of Visionary Investigators Network as a clinical research site participating in the Company’s Phase 2 CALMA trial evaluating IGC-AD1 for the treatment of agitat...
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
- Practice integrated neurology network expands enrollment capacity - POTOMAC, MARYLAND / ACCESS Newswire / February 23, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today ann...